DexCom, Inc. with price, financials, news flow, and insider context in one page.
DexCom, Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where DXCM sits inside Healthcare and Medical Devices, and the key financial markers that matter before moving into a fuller research workflow.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
This page is structured for research context, not a trade call. It gives you a clean read on where DXCM sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 1.19B | 199.5M | 449M |
| Q4 2025 | 1.26B | 267.3M | 192.1M |
| Q3 2025 | 1.21B | 283.8M | 579.4M |
| Q2 2025 | 1.16B | 179.8M | 208.9M |
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
DexCom, Inc. (DXCM) — questions investors ask
What is the current stock price of DexCom, Inc. (DXCM)?
DexCom, Inc. (DXCM) is trading at $70.14, up 2.17% in the latest session. The live price and one-year chart on this page update through the trading day.
What is DexCom, Inc.'s market capitalization?
DexCom, Inc. has a market capitalization of about 27.07B, derived from the latest share price and shares outstanding.
When is DexCom, Inc.'s next earnings date?
DexCom, Inc. is next expected to report earnings on Jul 29, 2026. The DXCM earnings page tracks the estimate and reporting history.
What is DexCom, Inc.'s P/E ratio?
DexCom, Inc. trades at a forward price-to-earnings ratio of 22.75 — one measure of how the market is pricing its future earnings.
What is DXCM's 52-week trading range?
Over the past 52 weeks, DXCM has traded between $54.11 and $89.98.
What sector is DexCom, Inc. in?
DexCom, Inc. operates in the Healthcare sector, within the Medical Devices industry.
What is the analyst price target for DXCM?
The mean analyst price target for DXCM is $85.24, with an overall analyst view of Strong Buy.
A public stock page should answer the first research questions before asking for a signup.
This DXCM page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.